Class Period: Aug 2, 2016 to Nov 16, 2016
Lead Plaintiff Deadline: Mar 6, 2017
Summary of Case:
A securities class action has been filed against Endologix, Inc. securities (NASDAQ:ELGX) on behalf of purchasers of Endologix, Inc. securities (NASDAQ:ELGX) from August 2, 2016 through November 16, 2016. This case has been filed in the USDC - C.D. Cal.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Endologix did not have the requisite clinical data for FDA premarket approval of its Nellix® EndoVascular Aneurysm Sealing System; and (2) as a result, Endologix's public statements were materially false and misleading at all relevant times. On November 16, 2016, Endologix announced that the FDA requested two-year follow-up data on patients enrolled in the EVAS-FORWARD-IDE study to assess Nellix. On this news, shares of Endologix fell $2.02 per share or over 20% to close at $7.82 per share on November 16, 2016, damaging investors.
If you purchased this company's shares during the Class Period and suffered a loss or for further information about the case, please review the links below.